Provided is a plant exudate, methods for obtaining a plant exudate by inducing the plant to secrete an exudate and systems for the collection of a plant exudate which include: one or more plant container including at least two discrete compartments each configured to accommodate a split root of a plant, the compartments being a root stimulating compartment including one or more input being in fluid communication with at least a source of a plant root stimulant, and a root exudate harvesting compartment, and a root exudate collection compartment in fluid communication with the root exudate harvesting compartment.

There are described plants of Papaver somniferum having reduced expression or activity of magnesium chelatase where-by the plants yield poppy straw having an altered alkaloid profile. In embodiments of the plants the reduced expression or activity of magnesium chelatase is associated with a trait for a lightened leaf colour. There are also described methods for producing the plants, and poppy straw, latex, concentrate of poppy straw and opium from the plants.

There are described plants of Papaver somniferum having reduced expression or activity of magnesium chelatase where-by the plants yield poppy straw having an altered alkaloid profile. In embodiments of the plants the reduced expression or activity of magnesium chelatase is associated with a trait for a lightened leaf colour. There are also described methods for producing the plants, and poppy straw, latex, concentrate of poppy straw and opium from the plants.

Disclosed herein are herbal formulations for relief from symptoms of skin disease. The formulations can also be combined with an active or inactive pharmaceutical ingredient, and/or a pharmaceutically acceptable excipient.

Disclosed herein are herbal formulations for relief from symptoms of skin disease. The formulations can also be combined with an active or inactive pharmaceutical ingredient, and/or a pharmaceutically acceptable excipient.

Provided is an A.C.C. extract from a combination of medicinal herbs, which are Phellodendron bark, Scutellaria baicalensis, Paeonia lactiflora Pall, Dictamnus dasycarpus Turcz, Anemarrhena asphodeloides, Alumen, Dryobalanops aromatica Gaertner, Mentha arvensis var. piperascens, Inula helenium, Syringa velutina var. kamibayashii, Corydalis incisa, Eclipta prostrata, Lonicera japonica, and Glycyrrhiza uralensis, and a composition having the same as an active ingredient. The A.C.C. extract of the present invention reduces production of TNF- IL-1 and IL-6, thereby regulating the expression of iNOS and thus exhibiting an anti-inflammatory effect inhibiting NO production. Also clinically, the A.C.C. extract of the present invention is a substance that alleviates symptoms such as diaper rash and miliaria through anti-inflammatory and antimicrobial activitities and can be used as an effective anti-inflammatory agent.

Provided is an A.C.C. extract from a combination of medicinal herbs, which are Phellodendron bark, Scutellaria baicalensis, Paeonia lactiflora Pall, Dictamnus dasycarpus Turcz, Anemarrhena asphodeloides, Alumen, Dryobalanops aromatica Gaertner, Mentha arvensis var. piperascens, Inula helenium, Syringa velutina var. kamibayashii, Corydalis incisa, Eclipta prostrata, Lonicera japonica, and Glycyrrhiza uralensis, and a composition having the same as an active ingredient. The A.C.C. extract of the present invention reduces production of TNF- IL-1 and IL-6, thereby regulating the expression of iNOS and thus exhibiting an anti-inflammatory effect inhibiting NO production. Also clinically, the A.C.C. extract of the present invention is a substance that alleviates symptoms such as diaper rash and miliaria through anti-inflammatory and antimicrobial activitities and can be used as an effective anti-inflammatory agent.

An application of an oral pharmaceutical composition in manufacturing of a medication for regulating fibroblast growth and treating or preventing organ fibrosis. The pharmaceutical composition comprises a homogeneous mixture of an edible oil, beeswax, and -sitosterol, wherein the beeswax forms microcrystals, and on the basis of the total weight of the composition, the content of the beeswax is 0.5-50% and the content of -sitosterol is 0.1%-20%.

An application of an oral pharmaceutical composition in manufacturing of a medication for regulating fibroblast growth and treating or preventing organ fibrosis. The pharmaceutical composition comprises a homogeneous mixture of an edible oil, beeswax, and -sitosterol, wherein the beeswax forms microcrystals, and on the basis of the total weight of the composition, the content of the beeswax is 0.5-50% and the content of -sitosterol is 0.1%-20%.

An application of an oral pharmaceutical composition in manufacturing of a medication for regulating fibroblast growth and treating or preventing organ fibrosis. The pharmaceutical composition comprises a homogeneous mixture of an edible oil, beeswax, and -sitosterol, wherein the beeswax forms microcrystals, and on the basis of the total weight of the composition, the content of the beeswax is 0.5-50% and the content of -sitosterol is 0.1%-20%.